ArticleTropical medicine and health2026
Longitudinal urinary LAM measurements in pulmonary tuberculosis patients: preliminary observations.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.Frontiers in antibiotics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring treatment response in pulmonary tuberculosis (TB) is critical, but non-invasive biomarkers are limited for patients unable to produce sputum.
objectiveTo evaluate the utility of the PATHFAST TB LAM Ag assay in urine for diagnosis and treatment monitoring of pulmonary TB.
methodsNine patients with confirmed TB at the University Hospital of Larissa, Greece, were followed longitudinally. Urine samples were collected at treatment initiation and at weeks 2, 4, 8, 12, 16, 20, and 24. Lipoarabinomannan (LAM) concentrations were measured using the PATHFAST TB LAM Ag assay; values ≥ 10 pg/mL were considered positive.
resultsUrinary LAM positivity peaked between weeks 4 and 12. Three kinetic patterns emerged: (i) early pronounced decline in patients with high baseline LAM; (ii) modest decreases in intermediate baseline patients; and (iii) variable or rising trajectories in low-baseline patients. Patterns mirrored previously reported sputum LAM kinetics. One patient treated on clinical criteria alone showed baseline positivity, and two patients with non-tuberculous mycobacterial infection also tested positive.
conclusionsUrinary LAM kinetics closely mirror sputum-derived patterns, supporting urine as a non-invasive specimen for serial TB monitoring. Interpretation of low-baseline results requires caution, and further studies with larger cohorts are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.